Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Sheffield Mental Health Nurse Jailed 21 Months For Fraud
A man who used a forged document to obtain an NHS bursary and train as a mental health nurse has been sentenced to 21 months in prison for fraud at Sheffield Crown Court (18 May 2009) after a joint investigation by NHS Counter Fraud and the UK Border Agency.
generic viagra online
Spanish Prostitutes Least Likely To Use Condoms
The Centre for Epidemiological Studies into Sexually-Transmitted Diseases and AIDS in Catalonia (CEEISCAT) started a pioneering study in Spain in 2005 to look into the prevalence of sexually-transmitted diseases (STDs) among female sex workers (SWs). The objective was to monitor the rates of infection with both HIV and other diseases over time, as well as the prevalence of risky behaviour.
News of the day
Ongoing Refugee Crisis In Pakistan Overwhelms Health System
The AP/Washington Post examines how the millions of Pakistani refugees fleeing from the army"s offensive against the Taliban in the northwest of the country are overwhelming the country"s health care system. "The crisis has exhausted doctors, used up limited supplies of medicines and buried hospitals in a mountain of red tape as they try to get money and medicine for the crisis" pushing the entire health system to the brink of collapse, the AP/Washington Post writes.
Medical Devices

Advanced Prostate Cancer - New Review On PROSTVAC(TM) Published By Key Investigators From NCI

A just published Review in the publication "Expert Opinion on Investigational Drugs", Volume 18, Issue 7 2009, confirms the previous published information on PROSTVAC(TM). This is the most comprehensive and updated Review on PROSTVAC(TM) so far. Quote from the article: "Preliminary clinical trials have indicated negligible toxicity, and Phase II trials have suggested a survival benefit after treatment with PROSTVAC(TM), especially in patients with indolent disease characteristics." Anders Hedegaard, President & CEO of Bavarian Nordic said: "We are very pleased that the scientific experts once again confirm their positive view on PROSTVAC(TM) and the potential use of the vaccine in earlier stages of the disease. We are looking forward to publish more data at a later stage." Background information: PROSTVAC(TM) is a therapeutic vaccine moving into late stage clinical development that has the potential to extend the lives of people with advanced prostate cancer. Administered subcutaneously, it induces a specific, targeted immune response that attacks prostate cancer cells. Conventional chemotherapy currently used to treat prostate cancer has limited survival rates and is often associated with numerous side effects. In contrast, PROSTVAC(TM) has the potential to extend survival with improved quality of life. PROSTVAC is being developed in collaboration with the National Cancer Institute under a Cooperative Research and Development Agreement with Bavarian Nordic"s U.S.-based subsidiary, BN ImmunoTherapeutics. In clinical trials to date PROSTVAC(TM) and related PSA containing poxviral vaccines have been investigated in more than 500 patients for 10 years. Bavarian Nordic


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009